ISRCTN72792659已完成不适用
Prospective randomised phase II clinical trial of epirubicin, cisplatin, continuous infusional 5-fluorouracil (ECF) versus epirubicin, cisplatin and capecitabin (ECX) in patients with advanced gastric cancer
Ministry of Higher Education, Science and Technology (Slovenia)0 个研究点目标入组 80 人开始时间: 2008年11月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Both males and females, age 18 years or older
- •2. Histologically confirmed advanced gastric cancer
- •3. Performance status of 0-2
- •4. Adequate bone marrow function
- •5. Adequate renal, hepatic function
- •7. Normal cardiac function
- •8. Estimated life expectancy more than 3 months
排除标准
- •1. Performance status more than 2
- •2. Patients not recovered from operation
- •3. Patients with unresolved intestinal obstruction
- •4. Malabsorption syndrome
- •5. Pregnancy
- •6. Breastfeeding or childbearing potential without using adequate contraception
- •7. Cardiovascular diseases (New York Heart Association [NYHA] III-IV)
- •8. Impaired renal function
- •9. Liver diseases
- •10. Active hepatitis (hepatitis B, hepatitis C)
- •11. HIV positive
- •12. Other active infection
研究者
相似试验
尚未招募
不适用
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemiaacute myeloid leukemiaACTRN12620000850976epean Blue Mountains Local Health District134
已完成
2 期
Phase II randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancerMetastatic breast cancerJPRN-UMIN000027382Kyushu Breast Cancer Study Group (KBC-SG)90
进行中（未招募）
1 期
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
已完成
不适用
Phase II randomized clinical trial for the purpose of examining the protective efficacy of the non-alcoholic fatty liver development by pancrelipase preparation being given for pancreatic cancer patients who underwent pancreaticoduodenectomy or total pancreatectomy.To assume the decreased rate of post-operative non-alcoholic fatty liver incidence in pancreatic cancer patients with the prophylactic administration of the pancrelipase preparation.JPRN-UMIN000019817Department of Surgery, Kansai Medical University80
招募中
2 期
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)Multiple myeloma2024-514527-42-00Karolinska Institutet, Karolinska Institutet62